AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Patch Testing on Immunosuppressives: Should You? Can You?

Description

The discussion revolves around the challenges of conducting patch testing for allergic contact dermatitis in patients on immunosuppressive drugs. Various medications, including older drugs like prednisone and newer therapies such as dupilumab and JAK inhibitors, can affect the immune response necessary for meaningful patch test results. The speaker highlights the importance of ensuring that the skin is clear of active rash before testing to avoid misleading results. They discuss specific guidelines on when to avoid patch testing, recommending that immunosuppressants be minimized or discontinued to improve the accuracy of results. Recent studies have shown that while low doses of prednisone (5-10 mg) and methotrexate are generally acceptable during testing, higher doses can suppress immune reactions. The talk emphasizes a balance between managing dermatitis with immunosuppressants and the need for accurate patch testing to identify any allergic triggers that can exacerbate skin conditions. Ultimately, decisions regarding patch testing in the context of immunosuppressive therapy should be personalized, with careful consideration of the risks and benefits involved.

View more

Conclusions

  • Patch testing is dependent on the body's ability to mount an immune reaction, which can be suppressed by immunosuppressive medications.
  • Immunosuppressants like prednisone at doses above 10 mg may reduce the reliability of patch tests, while doses below 10 mg are generally acceptable for testing.
  • Methotrexate does not significantly affect patch test results at lower doses, making it reasonably safe to patch test while on this medication.
  • Short bursts of cyclosporine may not adversely affect patch testing, but caution is advised due to its potent immunosuppressive effects.
  • Azathioprine appears to have minimal impact on patch testing results, with most patients maintaining their positive reactions even after treatment.
  • Dupilumab may result in some loss of positive patch test reactions, though findings are mixed and allergen-dependent, requiring careful consideration before discontinuing it for testing.
  • JAK inhibitors are likely detrimental to patch testing outcomes and should generally be avoided during such evaluations.
  • Patients experiencing dermatitis while on immunosuppressive therapy can often still produce relevant patch test reactions.
  • Brites GS, Ferreira I, Sebastião Al, Silva A, Carrascal M, Neves BM, Cruz MT. Allergic contact dermatitis: From pathophysiology to development of new preventive strategies. Pharmacol Res. 2020 Dec;162:105282. doi: 10.1016/j.phrs.2020.105282. Epub 2020 Nov 5. PMID: 33161140.
  • Fowler JF Jr, Maibach HI, Zirwas M, Taylor JS, Dekoven JG, Sasseville D, Warshaw EM, Belsito DV, Storrs FJ, Zug KA, Pratt MD, Mathias CG, Deleo VA, Fransway AF, Myers F, Marks JG. Effects of immunomodulatory agents on patch testing: expert opinion 2012. Dermatitis. 2012 Nov-Dec;23(6):301-3.
  • Mufti A, Lu JD, Sachdeva M, Zaaroura H, Kashetsky N, Yeung J, Maibach HI, DeKoven J. Patch Testing During Immunosuppressive Therapy: A Systematic Review. Dermatitis. 2021 Nov-Dec 01;32(6):365-374.
  • Anveden I, Lindberg M, Andersen KE, Bruze M, Isaksson M, Liden C, Sommerlund M, Wahlberg JE, Wilkinson JD, Willis CM. Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis. 2004 May;50(5):298-303.
  • Rosmarin D, Gottlieb AB, Asarch A, Scheinman PL. Patch-testing while on systemic immunosuppressants. Dermatitis. 2009 Sep-Oct;20(5):265-70. PMID: 19808001.
  • Roberson F, Luis C, Cruzval-O'Reilly E, Lugo-Somolinos A. Methotrexate and Patch Testing: A Retrospective Review. Dermatitis. 2022 Feb 15.
  • Vena GA, Foti C, Piazzola L, Angelini G. Can cyclosporin A help distinguish allergic from irritant patch test reactions? Contact Dermatitis. 1994 Oct;20(5):265-70. PMID: 7842682.
  • Garg V, Brod B, Gaspari AA. Patch testing: Uses, systems, risks/benefits, and its role in managing the patient with contact dermatitis. Clin Dermatol. 2021 Jul-Aug;39(4):580-590. doi: 10.1016/j.clindermatol.2021.03.005. Epub 2021 Mar 26. PMID: 34809764.
  • Verma KK, Bhari N, Sethuraman G. Azathioprine does not influence patch test reactivity in Parthenium dermatitis. Contact Dermatitis. 2016 Jan;74(1):64-5. doi: 10.1111/cod.12466. PMID: 26690284.
  • Sjövall P, Christensen OB. Local and systemic effect of ultraviolet irradiation (UVB and UVA) on human allergic contact dermatitis. Acta Derm Venereol. 1986;66(4):290-4. PMID: 2430397.
  • Daunton A, Williams J. The impact of ultraviolet exposure on patch testing in clinical practice: a case-control study. Clin Exp Dermatol. 2020 Jan;45(1):25-29. doi: 10.1111/ced.13987. Epub 2019 Jun 26. PMID: 31025766.
  • Kim N, Notik S, Gottlieb AB, Scheinman PL. Patch test results in psoriasis patients on biologics. Dermatitis. 2014 Jul-Aug;25(4):182-90.
  • Raffi J, Suresh R, Botto N, Murase JE. The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review. J Am Acad Dermatol. 2021 Jun;84(6):1772-1776. doi: 10.1016/j.jaad.2021.02.044. Epub 2021 Feb 19. PMID: 33617912.
  • Mainville L, Veillette H, Houle MC. Sequential patch testing in a patient treated with dupilumab then with upadacitinib: Differences in patch test results as well as in disease control. Contact Dermatitis. 2023 Jan 16. doi: 10.1111/cod.14278. Epub ahead of print. PMID: 36645261.